Fibrosis index nine superiority for cirrhosis in hypopituitarism: Clinical validation of endocrine liver triage tool

doi:10.3748/wjg.119442

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 28

This Article

(16)

(12)

(0)

(223)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Jul 28, 2026; 32(28): 119442
Published online Jul 28, 2026. doi: 10.3748/wjg.119442

Table 2 Liver-related parameters and non-invasive fibrosis scores in the cirrhosis and non-cirrhosis groups

Variable	Cirrhosis group (n = 19)	Non-cirrhosis group (n = 16)	P value
Diabetes	7 (36.8)	0 (0)	0.003^b
AST (IU/L)	53 (35.5, 63)	32 (26.75, 50)	0.033^a
ALT (IU/L)	36 (23, 63)	27.5 (15, 55.25)	0.417
GGT (IU/L)	85 (58, 176)	26 (16, 44.25)	< 0.0001^c
ALP (IU/L)	108 (82, 205)	121 (70, 205)	0.938
Alb (g/L)	46 (40, 48)	47.5 (46, 49)	0.109
INR	1.09 (1.05, 1.16)	1.02 (0.99, 1.07)	0.027^a
Bilirubin (μmol/L)	13.6 (10.6, 25)	10.9 (9.33, 17.68)	0.066
Platelet (G/L)	102 (58, 183)	255 (217.8, 320)	< 0.0001^c
HA (ng/mL)	157.5 (92, 247.8; n = 18)	63 (40.5, 87.75; n = 14)	0.0002^c
PIIINP (ng/mL)	16 (9.3, 26.25; n = 18)	16 (9, 23; n = 15)	0.800
CIV (ng/mL)	136 (103.8, 176.8; n = 18)	81 (50, 106; n = 15)	0.0003^c
LN (ng/mL)	163.5 (105, 196.8)	122 (100, 156; n = 15)	0.100
FIB-4	2.15 (1.20, 4.05)	0.48 (0.34, 0.75)	< 0.0001^c
APRI	1.05 (0.59, 2.17)	0.34 (0.27, 0.4)	< 0.0001^c
FIB-9	3.75 (1.89, 3.99)	0.49 (0.02, 1.61)	< 0.0001^c
LSM (kPa)	23.2 (15.8, 31.9; n = 15)	5.7 (3.9, 6.8; n = 5)	0.0001^c

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

Data are presented as median (interquartile range) for continuous variables and as n (%) for categorical variables. All values are based on non-missing data unless otherwise indicated. Alb: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase; INR: International normalized ratio; HA: Hyaluronic acid; PIIINP: Procollagen III N-terminal peptide; CIV: Type IV collagen; LN: Laminin; FIB-4: Fibrosis-4; APRI: Aspartate aminotransferase-to-platelet ratio index; FIB-9: Fibrosis-9; LSM: Liver stiffness measurement.

Full Size Table

Citation: Li T, Wang X, Nie M, Han Q, Wu XY, Mao JF. Fibrosis index nine superiority for cirrhosis in hypopituitarism: Clinical validation of endocrine liver triage tool. World J Gastroenterol 2026; 32(28): 119442
URL: https://www.wjgnet.com/1007-9327/full/v32/i28/119442.htm
DOI: https://dx.doi.org/10.3748/wjg.119442

Li T, Wang X, Nie M, Han Q, Wu XY, Mao JF. Fibrosis index nine superiority for cirrhosis in hypopituitarism: Clinical validation of endocrine liver triage tool. World J Gastroenterol 2026; 32(28): 119442 [DOI: 10.3748/wjg.119442]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.